scholarly journals Neutrophil to lymphocyte ratio predicts short- and long-term mortality following revascularization therapy for ST elevation myocardial infarction

2014 ◽  
Vol 21 (5) ◽  
pp. 500-508 ◽  
Author(s):  
Abhishek C. Sawant ◽  
Prabhat Adhikari ◽  
Swapna R. Narra ◽  
Shantanu S. Srivatsa ◽  
Paul K. Mills ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Neutrophil To Lymphocyte Ratio ◽  
St Elevation Myocardial Infarction ◽  
Lymphocyte Ratio ◽  
Short And Long Term ◽  
St Elevation ◽  
Revascularization Therapy ◽  
Long Term Mortality

Impact of age on short- and long-term mortality of patients with ST-elevation myocardial infarction in the VIENNA STEMI network

2017 ◽  
Vol 130 (5-6) ◽  
pp. 172-181 ◽  
Author(s):  
Paul Michael Haller ◽  
Bernhard Jäger ◽  
Serdar Farhan ◽  
Günter Christ ◽  
Wolfgang Schreiber ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
St Elevation Myocardial Infarction ◽  
Short And Long Term ◽  
St Elevation ◽  
Long Term Mortality

scholarly journals Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989–2018): The Ruti-STEMI-Shock Registry

2020 ◽  
Vol 9 (8) ◽  
pp. 2398
Author(s):  
Cosme García-García ◽  
Teresa Oliveras ◽  
Nabil El Ouaddi ◽  
Ferran Rueda ◽  
Jordi Serra ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cardiogenic Shock ◽  
St Elevation Myocardial Infarction ◽  
Mortality Trends ◽  
All Cause Mortality ◽  
Short And Long Term ◽  
St Elevation ◽  
Multivariable Adjustment ◽  
Long Term Mortality

Aims: Cardiogenic shock (CS) is an ominous complication of ST-elevation myocardial infarction (STEMI), despite the recent widespread use of reperfusion and invasive management. The Ruti-STEMI-Shock registry analysed the prevalence of and 30-day and 1-year mortality rates in ST-elevation myocardial infarction (STEMI) complicated by CS (STEMI-CS) over the last three decades. Methods and Results: From February 1989 to December 2018, 493 STEMI-CS patients were consecutively admitted in a well-defined geographical area of ~850,000 inhabitants. Patients were classified into six five-year periods based on their year of admission. STEMI-CS mortality trends were analysed at 30 days and 1 year across the six strata. Cox regression analyses were performed for comparisons. Mean age was 67.5 ± 11.7 years; 69.4% were men. STEMI-CS prevalence did not decline from period 1 to 6 (7.1 vs. 6.2%, p = 0.218). Reperfusion therapy increased from 22.5% in 1989–1993 to 85.4% in 2014–2018. Thirty-day all-cause mortality declined from period 1 to 6 (65% vs. 50.5%, p < 0.001), with a 9% reduction after multivariable adjustment (HR: 0.91; 95% CI: 0.84–0.99; p = 0.024). One-year all-cause mortality declined from period 1 to 6 (67.5% vs. 57.3%, p = 0.001), with an 8% reduction after multivariable adjustment (HR: 0.92; 95% CI: 0.85–0.99; p = 0.030). Short- and long-term mortality trends in patients aged ≥ 75 years remained ~75%. Conclusions: Short- and long-term STEMI-CS-related mortality declined over the last 30 years, to ~50% of all patients. We have failed to achieve any mortality benefit in STEMI-CS patients over 75 years of age.

Sign in / Sign up

Export Citation Format

Share Document